CN108473577A - 多价fv抗体 - Google Patents

多价fv抗体 Download PDF

Info

Publication number
CN108473577A
CN108473577A CN201680073236.5A CN201680073236A CN108473577A CN 108473577 A CN108473577 A CN 108473577A CN 201680073236 A CN201680073236 A CN 201680073236A CN 108473577 A CN108473577 A CN 108473577A
Authority
CN
China
Prior art keywords
ser
gly
thr
val
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680073236.5A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯蒂娜·埃尔旺格
伊维卡·法斯克
索斯藤·甘特克
托马斯·穆勒
埃里希·拉伊科维奇
乌维·罗伊施
马丁·特里德
迈克尔·维柴尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Therapeutics AG filed Critical Affimed Therapeutics AG
Publication of CN108473577A publication Critical patent/CN108473577A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201680073236.5A 2015-10-13 2016-10-13 多价fv抗体 Pending CN108473577A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15189665.1 2015-10-13
EP15189665.1A EP3156417A1 (en) 2015-10-13 2015-10-13 Multivalent fv antibodies
PCT/EP2016/074642 WO2017064221A1 (en) 2015-10-13 2016-10-13 Multivalent fv antibodies

Publications (1)

Publication Number Publication Date
CN108473577A true CN108473577A (zh) 2018-08-31

Family

ID=54325413

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680073236.5A Pending CN108473577A (zh) 2015-10-13 2016-10-13 多价fv抗体

Country Status (13)

Country Link
US (1) US11572415B2 (enExample)
EP (2) EP3156417A1 (enExample)
JP (1) JP6936497B2 (enExample)
KR (1) KR20180057720A (enExample)
CN (1) CN108473577A (enExample)
AU (1) AU2016336866B2 (enExample)
BR (1) BR112018007445A2 (enExample)
CA (1) CA3001765A1 (enExample)
IL (1) IL258638B2 (enExample)
MX (1) MX2018004547A (enExample)
SG (2) SG10202004094VA (enExample)
WO (1) WO2017064221A1 (enExample)
ZA (1) ZA201802543B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114316060A (zh) * 2021-12-15 2022-04-12 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
CN114502203A (zh) * 2019-11-06 2022-05-13 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
WO2022174813A1 (zh) * 2021-02-19 2022-08-25 信达生物制药(苏州)有限公司 抗GPRC5DxBCMAxCD3三特异性抗体及其用途
CN115175938A (zh) * 2020-03-17 2022-10-11 西雅图免疫公司 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890041A1 (ru) 2015-06-15 2018-07-31 Нумаб Инновейшн Аг Гетеродимерный полиспецифичный формат антител
CN110799540B (zh) * 2017-06-25 2024-02-13 西雅图免疫公司 多特异性抗体及其制备和使用方法
CA3090464A1 (en) 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
AU2019243453B2 (en) * 2018-03-27 2024-05-02 Systimmune, Inc. Methods of making and using guidance and navigation control proteins
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies
MX2020010728A (es) 2018-04-13 2020-11-06 Affimed Gmbh Constructos de fusion de anticuerpos que se acoplan a celulas nk.
KR20200143730A (ko) * 2018-04-17 2020-12-24 인벤라 인코포레이티드 3가 삼중 특이성 항체 구조물
KR20210052494A (ko) 2018-08-27 2021-05-10 아피메트 게엠베하 항체 구조물이 사전 로드된 동결 보존된 nk 세포
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子
WO2021130383A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
CA3203468A1 (en) * 2020-12-03 2022-06-09 Amgen Inc. Immunoglobuline constructs with multiple binding domains
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
MX2024003808A (es) * 2021-09-29 2024-06-11 Modex Therapeutics Inc Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos.
US20230272069A1 (en) * 2022-02-28 2023-08-31 Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1173878A (zh) * 1995-10-16 1998-02-18 尤尼利弗公司 双功能或双价抗体片段类似物
EP1293514A1 (en) * 2001-09-14 2003-03-19 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
WO2012135345A1 (en) * 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
EP0739350B1 (en) * 1994-01-07 2008-02-27 Mochida Pharmaceutical Co., Ltd. Ligand that binds fas antigen
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US20030162709A1 (en) 2001-12-26 2003-08-28 Edmund Rossi Methods of generating multispecific, multivalent agents from VH and VL domains
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
TW200808351A (en) * 2006-07-13 2008-02-16 Chugai Pharmaceutical Co Ltd Cell death-inducing agents
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
RU2693078C2 (ru) * 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
HK1216894A1 (zh) 2012-12-28 2016-12-09 Abbvie Inc. 多價結合蛋白組合物
US20150017120A1 (en) * 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
EA201890041A1 (ru) * 2015-06-15 2018-07-31 Нумаб Инновейшн Аг Гетеродимерный полиспецифичный формат антител

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1173878A (zh) * 1995-10-16 1998-02-18 尤尼利弗公司 双功能或双价抗体片段类似物
EP1293514A1 (en) * 2001-09-14 2003-03-19 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
WO2012135345A1 (en) * 2011-03-28 2012-10-04 Sanofi Dual variable region antibody-like binding proteins having cross-over binding region orientation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INGO SCHUBERT ET AL.: "A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting", 《MABS》 *
UWE REUSCH ET AL.: "A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells", 《MABS》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114502203A (zh) * 2019-11-06 2022-05-13 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
CN114502203B (zh) * 2019-11-06 2024-07-19 成都百利多特生物药业有限责任公司 制导和导航控制蛋白及其制备和使用方法
CN115175938A (zh) * 2020-03-17 2022-10-11 西雅图免疫公司 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法
CN115175938B (zh) * 2020-03-17 2025-12-09 成都百利多特生物药业有限责任公司 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法
WO2022174813A1 (zh) * 2021-02-19 2022-08-25 信达生物制药(苏州)有限公司 抗GPRC5DxBCMAxCD3三特异性抗体及其用途
CN114316060A (zh) * 2021-12-15 2022-04-12 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用

Also Published As

Publication number Publication date
IL258638A (en) 2018-06-28
RU2018126966A (ru) 2020-02-10
BR112018007445A2 (pt) 2019-12-10
RU2018126966A3 (enExample) 2020-04-20
IL258638B (en) 2022-12-01
MX2018004547A (es) 2018-11-09
ZA201802543B (en) 2020-01-29
CA3001765A1 (en) 2017-04-20
US20190040155A1 (en) 2019-02-07
SG10202004094VA (en) 2020-05-28
AU2016336866B2 (en) 2023-05-25
SG11201803083XA (en) 2018-05-30
EP3362478A1 (en) 2018-08-22
JP2018537415A (ja) 2018-12-20
US11572415B2 (en) 2023-02-07
AU2016336866A1 (en) 2018-05-10
EP3156417A1 (en) 2017-04-19
JP6936497B2 (ja) 2021-09-15
WO2017064221A1 (en) 2017-04-20
IL258638B2 (en) 2023-04-01
KR20180057720A (ko) 2018-05-30

Similar Documents

Publication Publication Date Title
AU2016336866B2 (en) Multivalent Fv antibodies
US20220048994A1 (en) Trifunctional antigen-binding molecule
CN111527109B (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
AU2016206108B2 (en) Monomeric Fc domains
EP3600407A1 (en) Improved antigen binding receptors
CN103687879A (zh) 多价抗原结合fv分子
CA3207652A1 (en) Cytokine anchors for nkp46-binding nk cell engager proteins
Acheampong Bispecific antibody (bsAb) construct formats and their application in cancer therapy
RU2785766C2 (ru) Мультивалентные fv-антитела
RU2785766C9 (ru) Мультивалентные fv-антитела
HK1260025A1 (en) Multivalent fv antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1260025

Country of ref document: HK